Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHIT: Controlled Dengue Human Infection Model in Thailand
NCT05476757Phase 1Not yet recruiting
- Sponsor
- Mahidol University
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of rDEN2Δ30-7169 in dengue fever, sponsored by Mahidol University. Primary endpoint: Safety of rDEN2Δ30-7169 at 21 days. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
rDEN2Δ30-7169
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT05476757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476757.